Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. (LAL1811)
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Sponsor: Incyte Corporation
Listed as NCT01641107, this PHASE2 trial focuses on Acute Lymphoblastic Leukemia and BCR-ABL Positive and remains completed. Sponsored by Incyte Corporation, it has been updated 11 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Unknown Status PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Nov 2018 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Ancona, Italy , Ascoli Piceno, Italy , Avellino, Italy , Bergamo, Italy , Bologna, Italy , Cagliari, Italy , Catania, Italy , Ferrara, Italy , Florence, Italy and 28 more locations